The Court of Appeal of the Ninth Arbitration allowed the Russian pharmaceutical manufacturer Biochemist to produce an anti-HIV drug, dolutegravir, the volume of public procurement which in 2026 reached 8.44 billion rubles. According to Kommersant, American ViiV Health and the Japanese Shionogi were obliged to issue a non-inclusive license to the company, taking into account the presence of pending patents for methods of obtaining the drug. In just one year, the buildings of the Ministry of Health purchased 162.1 thousand annual courses of the drug, which is 10 thousand more than a year before.

The Court of Appeal of the Ninth Arbitration allowed the Russian pharmaceutical manufacturer Biochemist to produce an anti-HIV drug, dolutegravir, the volume of public procurement which in 2026 reached 8.44 billion rubles. According to Kommersant, American ViiV Health and the Japanese Shionogi were obliged to issue a non-inclusive license to the company, taking into account the presence of pending patents for methods of obtaining the drug. In just one year, the buildings of the Ministry of Health purchased 162.1 thousand annual courses of the drug, which is 10 thousand more than a year before.